| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |